Anthem Biosciences Q1FY27 Revised Results: Revenue ₹4,182 Mn, PAT ₹1,199 Mn

Anthem Biosciences Ltd has released its revised unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1FY27). The company reported consolidated revenue from operations of ₹4,182 Mn. EBITDA for the quarter stood at ₹1,755 Mn, achieving 39.6% margins, while Profit After Tax (PAT) was ₹1,199 Mn, with PAT margins at 27.1%. Chairman, MD, and CEO, Ajay Bhardwaj, noted that the results reflect timing shifts in deliveries but emphasized strong underlying demand and a commitment to sustaining revenue growth. The company also achieved year-on-year improvement in EBITDA and PAT margins due to disciplined focus on cost efficiencies and productivity.